Tech Company Financing Transactions
Synthekine Funding Round
The Column Group joined a $100 million Series C capital raise for Synthekine. The financing was announced on 1/6/2023.
Transaction Overview
Company Name
Announced On
1/6/2023
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series C
Investors
The Column Group (Lead Investor) (Timothy Kutzkey)
Proceeds Purpose
The financing will be used to advance Synthekine's differentiated therapeutic pipeline, led by its alpha/beta-biased IL-2 partial agonist, STK-012, which is currently in a Phase 1 clinical trial. In addition, it will support upcoming clinical studies of its orthogonal IL-2 and CD19 CAR-T combination therapy, STK-009 + SYNCAR-001, which the company anticipates to begin early this year.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1505 O'Brien Dr.
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Website
Email Address
Not Recorded
Overview
Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific, selective and potent cytokine therapies. Our targeted protein engineering guided by our deep experience in immunology provides transformative immunotherapies for the treatment of cancer and autoimmune disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Debanjan Ray
Chief Medical Officer
Naiyer Rizvi
Vice President
Richard Murphy
Vice President
Gregory Yedinak
VP - Bus. Development
Martin Oft
VP - Finance
Robin Knifsend
VP - Operations
Christine Rocha
VP - R & D
Robert Kastelein
VP - R & D
Patrick Lupardus
Browse more venture capital transactions:
Prev: 1/6/2023: Miraxess venture capital transaction
Next: 1/6/2023: Wisdo Health venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs